TABLE 2.
Group N | Obese Patients n (% of Obese Total) |
Non-Obese Patients n (% of Non-Obese Total) |
P-Value | |
---|---|---|---|---|
# Patients | 155 | 40 | 115 | |
ALL Type | 0.31 | |||
Precursor B-Cell | 135 | 33 (82.5%) | 102(88.7%) | |
Precursor T-Cell | 20 | 7 (17.5%) | 13(11.3%) | |
Demographics | ||||
Age Group | 0.19 | |||
< 10 | 99 | 29 (72.5%) | 70(60.9%) | |
≥ 10 | 56 | 11 (27.5%) | 45 (39.1%) | |
Gender | 1.00 | |||
Male | 93 | 24 (60.0%) | 69 (60.0%) | |
Female | 62 | 16 (40.0%) | 46 (40.0%) | |
Race | 0.531 | |||
Caucasian | 139 | 34 (87.2%) | 105 (91.3%) | |
Black-American | 12 | 4 (10.3%) | 8 (7.0%) | |
Indian | 1 | 0 | 1 (0.9%) | |
Asian | 2 | 1 (2.6%) | 1 (0.9%) | |
Clinical Characteristics | ||||
CNS Disease Group | 0.132 | |||
1 | 145 | 35 (87.5%) | 110(95.7%) | |
2a | 8 | 5 (12.5%) | 3 (2.6%) | 0.033 |
2b | 1 | 0 | 1 (0.9%) | |
2c | 1 | 0 | 1 (0.9%) | |
NCI Risk Status Group | 0.35 | |||
Standard | 74 | 21 (52.5%) | 53 (46.1%) | |
High | 71 | 15 (37.5%) | 56 (48.7%) | |
Standard to High | 10 | 4 (10.0%) | 6 (5.2%) | |
Early Response Group | 0.87 | |||
Rapid | 133 | 34 (85.0%) | 99(86.1%) | |
Slow | 22 | 6 (15.0%) | 16 (13.9%) |
P-value reported for Caucasian vs. Non-Caucasian, excluded 1 patient race with not specified
P-value reported for CNS Disease Group 1 vs. Combined CNS Group 2a, 2b, and 2c
P-value reported for CNS Disease Group 1 vs. CNS group 2a between Obese vs. Non-Obese Groups